Norway will delay a decision on whether to resume the use of AstraZeneca's Covid-19 vaccine until 15 April, the Norwegian Institute of Public Health has said.
Authorities suspended the rollout of the vaccine on 11 March after five healthy younger inoculated people were hospitalised for a combination of blood clots, bleeding and a low count of platelets, three of whom later died. "We still need more information and more knowledge to reach a conclusion," Sara Viksmoen Watle, senior physician at the Norwegian Institute of Public Health, told Reuters. "Now we have more of an explanation for why the patients got these symptoms...